142 related articles for article (PubMed ID: 21684006)
1. Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
Knoebel RW; McQuary A; Becker P; Hendrie P; Petersdorf S; Appelbaum FR; Estey E
Leuk Res; 2011 Sep; 35(9):e164-6. PubMed ID: 21684006
[No Abstract] [Full Text] [Related]
2. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
3. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
[TBL] [Abstract][Full Text] [Related]
4. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine combinations as acute myeloid leukemia salvage therapy.
Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
Fontanelli G; Rocco M; Caracciolo F; Benedetti E; Buda G; Orciuolo E; Carulli G; Galimberti S; Azzarà A; Petrini M
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e13-7. PubMed ID: 24144836
[No Abstract] [Full Text] [Related]
9. Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
Grigoleit GU; Kapp M; Tan SM; Unzicker C; Einsele H; Mielke S; Topp MS; Stuhler G
Leuk Lymphoma; 2009 Dec; 50(12):2071-4. PubMed ID: 19886845
[No Abstract] [Full Text] [Related]
10. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
11. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
[TBL] [Abstract][Full Text] [Related]
12. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Cooper TM; Alonzo TA; Gerbing RB; Perentesis JP; Whitlock JA; Taub JW; Horton TM; Gamis AS; Meshinchi S; Loken MR; Razzouk BI
Cancer; 2014 Aug; 120(16):2482-9. PubMed ID: 24771494
[TBL] [Abstract][Full Text] [Related]
13. The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
Fozza C
Crit Rev Oncol Hematol; 2015 Mar; 93(3):237-45. PubMed ID: 25457773
[TBL] [Abstract][Full Text] [Related]
14. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
[TBL] [Abstract][Full Text] [Related]
15. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A
J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine-based consolidation therapy in AML.
Brower V
Lancet Oncol; 2017 Apr; 18(4):e201. PubMed ID: 28262461
[No Abstract] [Full Text] [Related]
17. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
Abbi KK; Rybka W; Ehmann WC; Claxton DF
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
[TBL] [Abstract][Full Text] [Related]
19. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Faderl S; Verstovsek S; Cortes J; Ravandi F; Beran M; Garcia-Manero G; Ferrajoli A; Estrov Z; O'Brien S; Koller C; Giles FJ; Wierda W; Kwari M; Kantarjian HM
Blood; 2006 Jul; 108(1):45-51. PubMed ID: 16403905
[TBL] [Abstract][Full Text] [Related]
20. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
